Company profile

Néovacs has become a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. With its innovative technology inducing a polyclonal immune response, protected by four patent families potentially until 2032, Néovacs focuses its clinical efforts on the development of IFNa-Kinoid for treating lupus and dermatomyositis. The group also carries out preclinical work on other therapeutic vaccines to treat autoimmune diseases, cancer, allergies and type 1 diabetes.

Source: Cofisem - Last Update: 12 Jun 2020
Key Executives
Chairman and Chief Executive Officer Hugo Brugière
Chief Operations Officer Vincent Serra
Chief Financial Officer Baptiste Pourtout
Investor Relations Director Charlène Masson
Source: Cofisem - Last Update: 18 May 2020
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales 15 148 142
Consumed purchases 327 417 746 445 652
Payroll 3,496 2,991 2,669 2,399 1,922
Operating profit -13,080 -18,329 -17,261 -11,279 -9,654
Income tax 2,775 4,022 3,394 2,565 2,306
Net income -10,780 -14,838 -13,932 -4,683 -7,513
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 12 Jun 2020
Shareholder information
Free float 76.76 %
Investisseurs Institutionnels 18.52 %
Novartis 1.14 %
Group-owned stock 0.83 %
Participations Besançon 0.80 %
Apicap 0.57 %
Source: Cofisem - Last Update: 07 Jun 2019

Financial analysis

Equity research report, in partnership with Morningstar

View Report

Address

Néovacs S.A.

3-5 Impasse Reille
FR-75014 Paris
France
Source: Cofisem - Last Update: 12 Jun 2020

Contact

Charlène Masson
Phone number: 00 33 153 10 93 00
Source: Néovacs S.A. - Last Update: 12 Jun 2020